in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. / Scherließ, Regina; Buske, Simon; Young, Katherine; Weber, Benjamin; Rades, Thomas; Hook, Sarah.

In: Vaccine, Vol. 31, No. 42, 01.10.2013, p. 4812-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Scherließ, R, Buske, S, Young, K, Weber, B, Rades, T & Hook, S 2013, 'in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations', Vaccine, vol. 31, no. 42, pp. 4812-9. https://doi.org/10.1016/j.vaccine.2013.07.081

APA

Scherließ, R., Buske, S., Young, K., Weber, B., Rades, T., & Hook, S. (2013). in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine, 31(42), 4812-9. https://doi.org/10.1016/j.vaccine.2013.07.081

Vancouver

Scherließ R, Buske S, Young K, Weber B, Rades T, Hook S. in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine. 2013 Oct 1;31(42):4812-9. https://doi.org/10.1016/j.vaccine.2013.07.081

Author

Scherließ, Regina ; Buske, Simon ; Young, Katherine ; Weber, Benjamin ; Rades, Thomas ; Hook, Sarah. / in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. In: Vaccine. 2013 ; Vol. 31, No. 42. pp. 4812-9.

Bibtex

@article{5622c9dbf97c4ba188efaf8f5ddacbe0,

title = "in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations",

abstract = "Vaccines utilising pure antigens instead of whole pathogens and alternative administration routes require the use of potent adjuvants and effective antigen delivery systems. Chitosan has been reported to act as both an adjuvant as well as a matrix for delivery systems. Chitosan is a natural product produced predominantly from crab shell and commercially available preparations vary in molecular weight, degree of deacetylation and purity. In this study, the impact of chitosan characteristics (molecular weight, degree of deacetylation, particle size, viscosity and impurities) on adjuvant activity were examined. It could be shown that the degree of immune response differed if different chitosan qualities were used and this could be attributed to different characteristics of the chitosan qualities: the immunoadjuvant effect of chitosan probably is a result of an interplay between chemical properties such as molecular weight and degree of deacetylation and physical properties such as particle size and preparation technique, which impacts characteristics such as solubility and viscosity. Hence, the chitosan quality to be used as adjuvant in vaccine preparations needs to be selected carefully.",

author = "Regina Scherlie{\ss} and Simon Buske and Katherine Young and Benjamin Weber and Thomas Rades and Sarah Hook",

year = "2013",

month = oct,

day = "1",

doi = "10.1016/j.vaccine.2013.07.081",

language = "English",

volume = "31",

pages = "4812--9",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "42",

}

RIS

TY - JOUR

T1 - in vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations

AU - Scherließ, Regina

AU - Buske, Simon

AU - Young, Katherine

AU - Weber, Benjamin

AU - Rades, Thomas

AU - Hook, Sarah

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Vaccines utilising pure antigens instead of whole pathogens and alternative administration routes require the use of potent adjuvants and effective antigen delivery systems. Chitosan has been reported to act as both an adjuvant as well as a matrix for delivery systems. Chitosan is a natural product produced predominantly from crab shell and commercially available preparations vary in molecular weight, degree of deacetylation and purity. In this study, the impact of chitosan characteristics (molecular weight, degree of deacetylation, particle size, viscosity and impurities) on adjuvant activity were examined. It could be shown that the degree of immune response differed if different chitosan qualities were used and this could be attributed to different characteristics of the chitosan qualities: the immunoadjuvant effect of chitosan probably is a result of an interplay between chemical properties such as molecular weight and degree of deacetylation and physical properties such as particle size and preparation technique, which impacts characteristics such as solubility and viscosity. Hence, the chitosan quality to be used as adjuvant in vaccine preparations needs to be selected carefully.

AB - Vaccines utilising pure antigens instead of whole pathogens and alternative administration routes require the use of potent adjuvants and effective antigen delivery systems. Chitosan has been reported to act as both an adjuvant as well as a matrix for delivery systems. Chitosan is a natural product produced predominantly from crab shell and commercially available preparations vary in molecular weight, degree of deacetylation and purity. In this study, the impact of chitosan characteristics (molecular weight, degree of deacetylation, particle size, viscosity and impurities) on adjuvant activity were examined. It could be shown that the degree of immune response differed if different chitosan qualities were used and this could be attributed to different characteristics of the chitosan qualities: the immunoadjuvant effect of chitosan probably is a result of an interplay between chemical properties such as molecular weight and degree of deacetylation and physical properties such as particle size and preparation technique, which impacts characteristics such as solubility and viscosity. Hence, the chitosan quality to be used as adjuvant in vaccine preparations needs to be selected carefully.

U2 - 10.1016/j.vaccine.2013.07.081

DO - 10.1016/j.vaccine.2013.07.081

M3 - Journal article

C2 - 23933339

VL - 31

SP - 4812

EP - 4819

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -

ID: 104835223

Department of Pharmacy